Beam Therapeutics (BEAM) Invested Capital (2019 - 2025)
Historic Invested Capital for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to $972.5 million.
- Beam Therapeutics' Invested Capital rose 2160.58% to $972.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $972.5 million, marking a year-over-year increase of 2160.58%. This contributed to the annual value of $741.9 million for FY2024, which is 2521.69% down from last year.
- According to the latest figures from Q3 2025, Beam Therapeutics' Invested Capital is $972.5 million, which was up 2160.58% from $1.1 billion recorded in Q2 2025.
- In the past 5 years, Beam Therapeutics' Invested Capital ranged from a high of $1.1 billion in Q1 2025 and a low of $495.5 million during Q1 2021
- Its 5-year average for Invested Capital is $838.2 million, with a median of $825.2 million in 2023.
- Its Invested Capital has fluctuated over the past 5 years, first surged by 31714.45% in 2021, then plummeted by 2521.69% in 2024.
- Beam Therapeutics' Invested Capital (Quarter) stood at $868.9 million in 2021, then dropped by 13.48% to $751.8 million in 2022, then skyrocketed by 31.97% to $992.1 million in 2023, then decreased by 25.22% to $741.9 million in 2024, then skyrocketed by 31.07% to $972.5 million in 2025.
- Its Invested Capital was $972.5 million in Q3 2025, compared to $1.1 billion in Q2 2025 and $1.1 billion in Q1 2025.